Balance Sheet Breakdown: Immunovant Inc (IMVT)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

After finishing at $26.41 in the prior trading day, Immunovant Inc (NASDAQ: IMVT) closed at $25.39, down -3.86%. In other words, the price has decreased by -$3.86 from its previous closing price. On the day, 2.77 million shares were traded. IMVT stock price reached its highest trading level at $26.47 during the session, while it also had its lowest trading level at $24.885.


Our goal is to gain a better understanding of IMVT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.70 and its Current Ratio is at 13.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on March 28, 2024, initiated with a Outperform rating and assigned the stock a target price of $50.

On March 13, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $50.

On February 20, 2024, JP Morgan started tracking the stock assigning a Overweight rating and target price of $51.JP Morgan initiated its Overweight rating on February 20, 2024, with a $51 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 22 ’24 when Salzmann Peter sold 16,163 shares for $29.65 per share. The transaction valued at 479,233 led to the insider holds 1,036,716 shares of the business.

Barnett Eva Renee sold 4,042 shares of IMVT for $119,845 on May 22 ’24. The Chief Financial Officer now owns 355,414 shares after completing the transaction at $29.65 per share. On May 22 ’24, another insider, Butchko Julia G., who serves as the Chief Development Officer of the company, sold 3,247 shares for $29.65 each. As a result, the insider received 96,274 and left with 448,380 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 3708311040 and an Enterprise Value of 3061125376.

Stock Price History:

Over the past 52 weeks, IMVT has reached a high of $45.58, while it has fallen to a 52-week low of $18.16. The 50-Day Moving Average of the stock is -15.08%, while the 200-Day Moving Average is calculated to be -23.00%.

Shares Statistics:

The stock has traded on average 1.16M shares per day over the past 3-months and 1638770 shares per day over the last 10 days, according to various share statistics. A total of 145.58M shares are outstanding, with a floating share count of 61.25M. Insiders hold about 58.06% of the company’s shares, while institutions hold 47.26% stake in the company. Shares short for IMVT as of 1715731200 were 9286588 with a Short Ratio of 7.99, compared to 1713139200 on 8508700. Therefore, it implies a Short% of Shares Outstanding of 9286588 and a Short% of Float of 13.28.

Most Popular